A man being treated with CAPD developed severe hyperkalemia associated with clofibrate-induced rhabdomyolysis. A total intake of 9.5 9 of clofibrate was complicated by a 100fold increase of CPK, a dramatic increase in muscular enzymes and a life-threatening serum K level of 7.9 mEq/l. Despite a significant peritoneal elimination of clofibrate, this man exhibited a supranormal serum level of free drug.
Get full access to this article
View all access options for this article.
References
1.
LangerT., LevyR.Acute muscular syndrome associated with administration of clofibrate.N Engl 1 Med1968; 279; 856.
2.
BridgmanI.F., RosenS.M., ThoyrI.M.Complications during clofibrate treatment of nephrotic syndrome hyperlipoproteinemia.Lancet1972; 2; 506.
3.
PieridesA.M., Alvarez-UdeF., KerrD.N.S.Clofibrate induced muscle damage in patients with chronic renal failure.Lancet1975; 2; 1279.
4.
Di GiulioS., BouluR., DrueckeT.Clofibrate treatment of hyperlipidemia in chronic renal failure.Clin Nephrol1977; 3: 304.
5.
HarvengtC., DesagerI.P.Pharmacokinetics and bioavailibility of simfibrate. a new clocibric acid derivative.Curr Ther Res1976; 19: 145.
6.
KijimaY., SasaokaT., KanayamaM., KubotaS.Untoward effects of clofibrate in hemodialysis patients.N Engl 1 Med1977; 296: 515 (letter).
Committee of Principal Investigation; WHO cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol.Mortality follow-up.Lancet1980; 2; 379.
